Dysplasia is a very imperfect biomarker for malignancy in Barrett's esophagus. Invasive
cancer has been found in 30–40% of esophagi resected because preoperative endoscopic …

BACKGROUND & AIMS: Endoscopic mucosal resection (EMR) is an important diagnostic,
staging, and therapeutic tool for patients with Barrett's esophagus (BE)–associated …

Endoscopic treatment of complicated Barrett's esophagus (BE) is becoming increasingly
popular worldwide based on favorable safety and oncologic outcomes. Indeed, endoscopic …

Endoscopic eradication therapy (EET) has revolutionized management of Barrett's
esophagus (BE)-associated neoplasia, traditionally treated by esophagectomy, which …

Background: Endoscopic resection (ER) is an important treatment modality for patients with
Barrett's esophagus (BE) containing high-grade dysplasia (HGD) or intramucosal cancer …

NS A risk-based algorithm, based upon multiple factors, is used to decide which patients
should undergo screening for Barrett esophagus (BE). These factors include the presence of …

Endoscopic resection has become the first-line therapy for the management of superficial
neoplasia throughout the gastrointestinal tract. Endoscopic mucosal resection (EMR) and …

Methods We queried a prospectively maintained database of all patients at our institution
undergoing EMR and ESD for dysplastic/neoplastic BE and abstracted relevant …

Barrett's esophagus (BE) is defined as a metaplastic change of the normal squamous lining
of the distal esophagus, with replacement of squamous epithelium by an intestinal-type …

The significance of this condition lies in its premalignant nature. Indeed, the annual
incidence of esophageal adenocarcinoma in patients with Barrett's esophagus without …